Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 327.35% from the stock’s previous close.

Separately, EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st.

Artelo Biosciences Stock Performance

Shares of ARTL stock opened at $1.17 on Wednesday. The firm has a market cap of $3.78 million, a P/E ratio of -0.35 and a beta of 1.35. Artelo Biosciences has a fifty-two week low of $1.00 and a fifty-two week high of $1.75. The business’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.28.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. As a group, equities analysts predict that Artelo Biosciences will post -2.41 EPS for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.